Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Clinical trial NCT06504459 · RECRUITING
Trial details
- NCT number
- NCT06504459
- Sponsor
- OHSU Knight Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-03
- Primary completion
- 2027-10-11
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.